PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/00	A2	(11) International Publication Number: WO 00/10547
		(43) International Publication Date: 2 March 2000 (02.03.00)

(21) International Application Number: PCT/EP99/06292

(22) International Filing Date: 18 August 1999 (18.08.99)

(30) Priority Data:

98115650.8	20 August 1998 (20.08.98)	EP
60/123,843	11 March 1999 (11.03.99)	US

(71) Applicant *(for all designated States except US)*: AVENTIS PHARMA S.A. [FR/FR]; 20, avenue Raymond Aron, F–92160 Antony (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BISSERY, Marie–Christine [FR/FR]; 5, rue Henri Poincaré, F–94400 Vitry sur Seine (FR). VRIGNAUD, Patricia [FR/FR]; 27, rue de la Clairière, F–77380 Combs la Ville (FR). ROBERTS, Simon [GB/GB]; 36 Fenton Grange, Harlow, Essex CM17 9PG (GB). BREALEY, Clive [GB/GB]; 99 Hemp Lane, Wigginton, Tring, Herts HP23 6HE (GB).

(74) Agent: LE PENNEC, Magali; Aventis Pharma, Direction des Brevets – Tri LE1 144, 20, avenue Raymond Aron, F–92165 Antony Cedex (FR).

(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: NEW USE OF TAXOID DERIVATIVES

(57) Abstract

The present invention relates a new use of taxoid derivatives. It relates more precisely to a method for treating abnormal cell proliferation of different resistant cell lines expressing multidrug resistance P–glycoprotein. This type of cells are representative of colon cancer cells. The products of the present invention are also usable to treat the colon cancer of mammals including men.